SCHEMBL3533267

SCHEMBL3533267

COC[C@H](C)NC(=O)c1ccc(Cl)nc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.62
HPGD P15428 2/20 0.58
RAB9A P51151 4/20 0.57
ALDH1A1 P00352 2/20 0.57
HTT P42858 1/20 0.57
HCAR3 P49019 1/20 0.51
POLB P06746 2/20 0.49
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
NAMPT P43490 3/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
MAPT P10636 2/20 0.47
PKM P14618 2/20 0.47
NPC1 O15118 1/20 0.46
MDM4 O15151 1/20 0.46
TP53 P04637 1/20 0.46
MDM2 Q00987 1/20 0.46
KDM4E B2RXH2 1/20 0.46
NAPRT Q6XQN6 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5423446 0.84 HPGD (0.58) HPGDRAB9AALDH1A1HTTHCAR3
SCHEMBL3409275 0.84 LMNA (0.66) LMNAHPGDRAB9AALDH1A1HTT
SCHEMBL6870509 0.84 LMNA (0.60) LMNARAB9AALDH1A1POLBMEN1
SCHEMBL9391489 0.80 LMNA (0.54) LMNARAB9AALDH1A1POLBMEN1
SCHEMBL24571838 0.78 LMNA (0.58) LMNARAB9AALDH1A1POLBMEN1
SCHEMBL3534465 0.78 LMNA (0.58) LMNARAB9AALDH1A1POLBMEN1
SCHEMBL3537584 0.78 LMNA (0.58) LMNARAB9AALDH1A1POLBMEN1
SCHEMBL13527490 0.77 RAB9A (0.56) LMNARAB9AALDH1A1POLBMEN1
SCHEMBL25529105 0.77 LMNA (0.56) LMNARAB9AALDH1A1POLBMEN1
SCHEMBL16109895 0.76 ALDH1A1 (0.67) HPGDRAB9AALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1654235-B1 3- AMINOCARBONYL, 6-PHENYL SUBSTITUTED PYRIDINE-1-OXIDES AS P38 KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-12-26 EP disclosed
US-7838540-B2 3-aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2010-11-23 US disclosed
US-20070161684-A1 3-Aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors SIMITHKLINE BEECHMAN CORPORATION (US) 2007-07-12 US disclosed
EP-1654235-A1 3- AMINOCARBONYL, 6-PHENYL SUBSTITUTED PYRIDINE-1-OXIDES AS P38 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-05-10 EP disclosed
WO-2005014550-A1 3- AMINOCARBONYL, 6-PHENYL SUBSTITUTED PYRIDINE-1-OXIDES AS P38 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161684-A1 3-Aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors MAPK1, MAPK3, MAPKAPK2 LMNA 3072/4885HPGD 680/4885RAB9A 1054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.